Dave Friend

Publications (1)

A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.

Menopause (New York, N.Y.)
Avec: Andrea Thurman , M Louise Hull , Bronwyn Stuckey , Jessica Hatheway , Nadene Zack , Christine Mauck , David Friend

Réseau de co-auteurs

Andrea Thurman 1 collaboration
M Louise Hull 1 collaboration
Bronwyn Stuckey 1 collaboration
Jessica Hatheway 1 collaboration
Nadene Zack 1 collaboration
Christine Mauck 1 collaboration
David Friend 1 collaboration